Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review.

ABSTRACT:

Background

Compared to conventional human basal insulin (neutral protamine Hagedorn; NPH) the long-acting analogue insulin glargine (GLA) is associated with a number of advantages regarding metabolic control, hypoglycaemic events and convenience. However, the unit costs of GLA exceed those of NPH. This study aims to systematically review the economic evidence comparing GLA with NPH in basal-bolus treatment (intensified conventional therapy; ICT) of type 1 diabetes in order to facilitate informed decision making in clinical practice and health policy.

Methods

A systematic literature search was performed for the period of January 1st 2000 to December 1st 2009 via Embase, Medline, the Cochrane Library, the databases GMS (German Medical Science) and DAHTA (Deutsche Agentur für H

SUBMITTER: Hagenmeyer EG 

PROVIDER: S-EPMC3200149 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature